Cover Image
市場調查報告書

胃食道逆流症(GERD)治療藥及相關設備全球市場的預測

Global Gerd Drugs and Devices Market Forecast 2018-2026

出版商 Inkwood Research 商品編碼 746146
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胃食道逆流症(GERD)治療藥及相關設備全球市場的預測 Global Gerd Drugs and Devices Market Forecast 2018-2026
出版日期: 2018年11月19日 內容資訊: 英文 140 Pages
簡介

本報告提供全球胃食道逆流症(GERD)治療藥及相關設備市場調查,市場概要,各治療藥類型、相關設備、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

第1章 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場範圍和定義
  • 市場成長要素
  • 市場阻礙因素
  • 市場機會
  • 市場課題
  • 胃食道逆流症(GERD)市場:各劑型
  • 胃食道逆流症(GERD)市場:各給藥途徑

第5章 胃食道逆流症(GERD)治療藥及相關設備市場:各市場區隔

  • 各治療藥類型
    • 解酸劑
    • 組織胺H2受體拮抗劑
    • 質子幫浦阻斷劑(PPI)
    • 消化管運動改善藥
  • 各醫療設備(品牌)
    • Digitrapper
    • Bravo
    • Stretta
    • LINX
    • MUSE
    • 其他

第6章 市場分析

  • 波特的五力分析
  • 開發平台治療藥
  • 法律規範
  • 專利分析
  • 市場機會分析

第7章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 其他地區
    • 南美
    • 中東、非洲

第8章 競爭情形

  • 企業簡介
    • ABBOTT LABORATORIES.
    • ASTRAZENECA
    • BAUSCH HEALTH (FORMERLY VALEANT PHARMACEUTICALS INTERNATIONAL
    • BOSTON SCIENTIFIC CORPORATION
    • CEMPRA INC.
    • DAEWOONG CO. LTD.
    • Eisai
    • GLAXOSMITHKLINE
    • IRONWOOD PHARMACEUTICALS, INC.
    • JOHNSON & JOHNSON
    • MERCK & CO., INC.
    • NOVARTIS
    • PFIZER, INC.
    • RAQUAL IA PHARMA INC.
    • 武田藥品工業
目錄
Product Code: 22491

KEY FINDINGS

Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus. The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively. The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027.

MARKET INSIGHTS

The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD. Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market. The market is segmented by dosage form and by administration of the drugs.

REGIONAL INSIGHTS

The global GERD Drug and devices market is spread over Europe, Asia-Pacific, North America, Latin America and the Middle East and Africa. The North American region has been proclaimed as the largest market for GERD drug and devices. The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.

COMPETITIVE INSIGHTS

Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge. Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. ANTACIDS DRUG CLASS HOLDS THE LARGEST MARKET SHARE
    • 3.2.2. BRAVO SYSTEM DEVICES ARE WIDELY USED

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. GROWING TREND OF SELF-MEDICATION
    • 4.2.2. INCREASING AWARENESS ABOUT GERD
    • 4.2.3. INCREASING OCCURRENCE OF GERD DISORDERS
    • 4.2.4. CHANGES IN LIFESTYLE
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. PATENT EXPIRY
    • 4.3.2. ADVERSE EFFECT OF PROTON PUMP INHIBITORS AND OTHER DRUGS
    • 4.3.3. PROTON PUMP INHIBITOR RESISTANCE
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASED PRACTICE OF GENERICS AND OTC DRUGS
    • 4.4.2. COST-EFFECTIVE OTC DRUGS
    • 4.4.3. OVERUSE OF MEDICATION AND DIETARY SUPPLEMENTS
  • 4.5. MARKET CHALLENGES
    • 4.5.1. USE OF COMPLEMENTARY AND ALTERNATIVE TREATMENTS
    • 4.5.2. PROBABILITY OF BUYING COUNTERFEIT DRUGS
  • 4.6. MARKET BY DRUGS DOSAGE FORM
  • 4.7. MARKET BY ROUTE OF ADMINISTRATION OF DRUGS

5. MARKET BY DRUGS AND DEVICES

  • 5.1. DRUG CLASS
    • 5.1.1. ANTACIDS
    • 5.1.2. H2 RECEPTOR BLOCKERS
      • 5.1.2.1. CIMETIDINE
      • 5.1.2.2. FAMOTIDINE
      • 5.1.2.3. NIZATIDINE
      • 5.1.2.4. RANITIDINE HCL
    • 5.1.3. PROTON PUMP INHIBITORS (PPI)
      • 5.1.3.1. NEXIUM
      • 5.1.3.2. PRILOSEC/ LOSEC
      • 5.1.3.3. ACIPHEX/ PARIET
      • 5.1.3.4. DEXILANT
      • 5.1.3.5. PROTONIX
      • 5.1.3.6. PREVACID
      • 5.1.3.7. ZEGERID
      • 5.1.3.8. OTHER GENERIC PPI
    • 5.1.4. PRO-KINETIC AGENTS
  • 5.2. DEVICES
    • 5.2.1. DIGITRAPPER
    • 5.2.2. BRAVO SYSTEM
    • 5.2.3. STRETTA
    • 5.2.4. LINX REFLUX MANAGEMENT SYSTEM
    • 5.2.5. MUSE (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM
    • 5.2.6. OTHER DEVICES

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCE MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE
    • 6.1.3. BARGAINING POWER OF SUPPLIERS
    • 6.1.4. BARGAINING POWER OF BUYERS
    • 6.1.5. THREAT OF COMPETITIVE RIVALRY
  • 6.2. PIPELINE DRUGS
  • 6.3. REGULATORY FRAMEWORK
  • 6.4. PATENT ANALYSIS
  • 6.5. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. THE UNITED KINGDOM
    • 7.2.2. GERMANY
    • 7.2.3. FRANCE
    • 7.2.4. ITALY
    • 7.2.5. SPAIN
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. JAPAN
    • 7.3.2. CHINA
    • 7.3.3. INDIA
    • 7.3.4. AUSTRALIA
    • 7.3.5. SOUTH KOREA
    • 7.3.6. REST OF ASIA PACIFIC
  • 7.4. REST OF THE WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST AND AFRICA

8. COMPETITIVE LANDSCAPE

  • 8.1. MARKET SHARE ANALYSIS
  • 8.2. COMPANY PROFILES
    • 8.2.1. ABBOTT LABORATORIES.
      • 8.2.1.1. COMPANY OVERVIEW
      • 8.2.1.2. PRODUCT PORTFOLIO
      • 8.2.1.3. SCOT ANALYSIS
      • 8.2.1.4. STRATEGIC INITIATIVES
    • 8.2.2. ASTRAZENECA
      • 8.2.2.1. COMPANY OVERVIEW
      • 8.2.2.2. PRODUCT PORTFOLIO
      • 8.2.2.3. SCOT ANALYSIS
      • 8.2.2.4. STRATEGIC INITIATIVES
    • 8.2.3. BAUSCH HEALTH (FORMERLY VALEANT PHARMACEUTICALS INTERNATIONAL, INC.)
      • 8.2.3.1. COMPANY OVERVIEW
      • 8.2.3.2. PRODUCT PORTFOLIO
      • 8.2.3.3. SCOT ANALYSIS
      • 8.2.3.4. STRATEGIC INITIATIVES
    • 8.2.4. BOSTON SCIENTIFIC CORPORATION
      • 8.2.4.1. COMPANY OVERVIEW
      • 8.2.4.2. PRODUCT PORTFOLIO
      • 8.2.4.3. SCOT ANALYSIS
      • 8.2.4.4. STRATEGIC INITIATIVES
    • 8.2.5. CEMPRA INC. (MERGED WITH MELINTA)
      • 8.2.5.1. COMPANY OVERVIEW
      • 8.2.5.2. PRODUCT PORTFOLIO
      • 8.2.5.3. SCOT ANALYSIS
      • 8.2.5.4. STRATEGIC INITIATIVES
    • 8.2.6. DAEWOONG CO. LTD.
      • 8.2.6.1. COMPANY PROFILES
      • 8.2.6.2. PRODUCT PORTFOLIO
      • 8.2.6.3. STRATEGIC INITIATIVES
    • 8.2.7. EISAI INC
      • 8.2.7.1. COMPANY OVERVIEW
      • 8.2.7.2. PRODUCT PORTFOLIO
      • 8.2.7.3. SCOT ANALYSIS
      • 8.2.7.4. STRATEGIC INITIATIVES
    • 8.2.8. GLAXOSMITHKLINE
      • 8.2.8.1. COMPANY OVERVIEW
      • 8.2.8.2. PRODUCT PORTFOLIO
      • 8.2.8.3. SCOT ANALYSIS
      • 8.2.8.4. STRATEGIC INITIATIVES
    • 8.2.9. IRONWOOD PHARMACEUTICALS, INC.
      • 8.2.9.1. COMPANY OVERVIEW
      • 8.2.9.2. PRODUCT PORTFOLIO
      • 8.2.9.3. SCOT ANALYSIS
      • 8.2.9.4. STRATEGIC INITIATIVES
    • 8.2.10. JOHNSON & JOHNSON
      • 8.2.10.1. COMPANY OVERVIEW
      • 8.2.10.2. PRODUCT PORTFOLIO
      • 8.2.10.3. SCOT ANALYSIS
      • 8.2.10.4. STRATEGIC INITIATIVES
    • 8.2.11. MERCK & CO., INC.
      • 8.2.11.1. COMPANY PROFILES
      • 8.2.11.2. PRODUCT PORTFOLIO
      • 8.2.11.3. SCOT ANALYSIS
      • 8.2.11.4. STRATEGIC INITIATIVES
    • 8.2.12. NOVARTIS
      • 8.2.12.1. COMPANY OVERVIEW
      • 8.2.12.2. PRODUCT PORTFOLIO
      • 8.2.12.3. SCOT ANALYSIS
      • 8.2.12.4. STRATEGIC INITIATIVES
    • 8.2.13. PFIZER, INC.
      • 8.2.13.1. COMPANY PROFILES
      • 8.2.13.2. PRODUCT PORTFOLIO
      • 8.2.13.3. SCOT ANALYSIS
      • 8.2.13.4. STRATEGIC INITIATIVES
    • 8.2.14. RAQUAL IA PHARMA INC.
      • 8.2.14.1. COMPANY OVERVIEW
      • 8.2.14.2. PRODUCT PORTFOLIO
      • 8.2.14.3. STRATEGIC INITIATIVES
    • 8.2.15. TAKEDA PHARMACEUTICALS COMPANY LIMITED
      • 8.2.15.1. COMPANY OVERVIEW
      • 8.2.15.2. PRODUCT PORTFOLIO
      • 8.2.15.3. SCOT ANALYSIS
      • 8.2.15.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1 GLOBAL GERD DRUGS AND DEVICES MARKET BY REGION 2018-2026 ($ MILLION)
  • TABLE 2 GLOBAL GERD DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2019-2027 ($ MILLION)
  • TABLE 3 GLOBAL DRUG CLASS MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL DRUG CLASS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL ANTACIDS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL H2 RECEPTOR BLOCKERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL H2 RECEPTOR BLOCKERS MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL PRO-KINETIC AGENTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL DEVICES MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL DEVICES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL DIGITRAPPER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL BRAVO SYSTEM MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL STRETTA (MEDERITHERAPEUTICS) MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL LINX® REFLUX MANAGEMENT SYSTEM (TORAX MEDICAL) MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL MUSE™ (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL OTHER DEVICES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL GERD DRUGS AND DEVICES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 20 NORTH AMERICA GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 22 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 23 REST OF THE WORLD GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL GERD DRUGS AND DEVICES MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
  • FIGURE 2 GLOBAL GERD DRUGS AND DEVICES MARKET SHARE BY DRUGS AND DEVICES 2017 & 2027 (%)
  • FIGURE 3 GLOBAL H2 RECEPTOR BLOCKERS MARKET BY CIMETIDINE 2019-2027 ($ MILLION)
  • FIGURE 4 GLOBAL H2 RECEPTOR BLOCKERS MARKET BY FAMOTIDINE 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL H2 RECEPTOR BLOCKERS MARKET BY NIZATIDINE 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL H2 RECEPTOR BLOCKERS MARKET BY RANITIDINE HCL 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY NEXIUM 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY PRILOSEC/ LOSEC 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY ACIPHEX/ PARIET 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY DEXILANT 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY PROTONIX 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY PREVACID 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY ZEGERID 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL PROTON PUMP INHIBITORS (PPI) MARKET BY OTHER GENERIC PPI 2019-2027 ($ MILLION)
  • FIGURE 15 PORTER'S FIVE FORCE MODEL
  • FIGURE 16 GLOBAL GERD DRUGS AND DEVICES MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 17 THE UNITED STATES GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 18 CANADA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 19 THE UNITED KINGDOM GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 20 GERMANY GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 21 FRANCE GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 22 ITALY GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 23 SPAIN GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 24 REST OF EUROPE GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 25 JAPAN GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 26 CHINA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 27 INDIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 AUSTRALIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 SOUTH KOREA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 REST OF ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 LATIN AMERICA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 MIDDLE EAST AND AFRICA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 GERD PPIS DRUGS PROVIDER COMPANY MARKET SHARE 2017 (%)
Back to Top